News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News 📰

Alcoholic Hepatitis Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: November 2024 || SKU: PH7239
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Get Free Sample

See how US Tariffs impact Alcoholic Hepatitis Treatment Market

Alcoholic Hepatitis Treatment Market is segmented By Drug Type (Monoclonal Antibodies, Corticosteroids, Anabolic Steroids, Sulfhydryl Drugs, Others), By Route of Administration (Injectable, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

 

Market Overview

The Global Alcoholic Hepatitis Treatment market is expected to reach at a high CAGR during the forecast period 2024-2031.

Alcoholic hepatitis is an inflammatory liver disorder that is induced by regular increased alcohol consumption. Processing extensive quantities of alcohol can impair liver cells, leading to swelling and scarring of the liver. The condition varies from mild or severe. In severe alcoholic hepatitis cases, an individual may need a liver transplant if they do not obtain treatment or do not cease drinking alcohol in the premature phases.

The optimal therapy of alcoholic hepatitis concentrates on decreasing inflammation via the usage of glucocorticoids such as prednisolone, perhaps in combination with N-acetyl cysteine or additional drugs that subdue the immune system. Currently, only short-term gains in survival can be anticipated no therapy has been encountered to improve patient survival past 3 months. Alcohol abstinence is crucial for long-term survival.

Market Scope

MetricsDetails
CAGRHigh
Market Size Available for Years2021-2030
Estimation Forecast Period2024-2031
Revenue UnitsValue (US$ Mn) 
Segments CoveredDrug Type, Route of Administration, Distribution Channel, and Region
Regions CoveredNorth America, Europe, Asia-Pacific, South America, and Middle East & Africa
Largest RegionNorth America
Fastest Growing RegionAsia-Pacific
Report Insights CoveredCompetitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

 

To Know More Insights - Download Sample

 

Market Dynamics

Growing Prevalence of Alcohol-Related Liver Diseases

The growing prevalence of alcohol-related liver diseases is expected to boost the global market growth during the forecast period. For instance, according to the BioMed Central Ltd Journal 2023, published metal analysis article conclusion the preponderance of alcohol-related liver disease worldwide in 2022 was 4.8%. The preponderance in men was 2.9%, which was more elevated than female (0.5%). Similarly, according to the NIH, in the United States, alcohol is the top reason for liver disease. It affects over 61% of the American population, and out of the 61%, about 10% to 12% are heavy drinkers. Moreover, around 88,000 individuals are affected with alcohol-related diseases yearly, making alcohol the fourth top preventable reason for death in the U.S.

Furthermore, the growing awareness about alcohol related diseases, market developments, increase in research investments and activities are also driving the global market growth during the forecast period. 

Stringent Regulatory Authorities 

The stringent regulatory authorities authorizing the drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.

Market Segment Analysis

The global alcoholic hepatitis treatment market is segmented based on drug type, route of administration, distribution channel and region.

Monoclonal Antibody Drug Type Expected to Dominate Market

Owing to the increase in monoclonal antibody drug-type treatment clinical investigations in liver diseases the segment is estimated to hold a large share of the global market. For instance, in February 2023, Imperial College London reported the beginning of a study of phase 2 clinical investigation for Canakinumab 150mg/ml solution for injection. The immediate purpose of the ISAIAH investigation is to examine the probable benefits of utilizing the IL-1β antibody, Canakinumab (injection solution), for treating alcoholic hepatitis.

Moreover, recent conclusions from the pivotal phase 3 IMbrave050 trial examining atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) in patients with early-stage hepatocellular carcinoma (HCC) at elevated threat of disease recurrence has encountered that the investigation fulfilled its immediate endpoint of recurrence-free survival (RFS). Also, 9 out of 10 patients of HCC are induced by chronic liver condition, such as includes alcohol-related liver disease, chronic hepatitis B and C infection, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and cirrhosis resulting from these disorders.

Market Geographical Share

North America is Expected to Dominate the Global Market

The increasing approvals and growing research activities of North America based key players are expected to boost the regional market growth dominating the global market. For instance, in August, 2023, Ocean’s small molecule nominee particularly prevents fibrosis advancement in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing standards, it was also granted patent for usage in IPF, HPS, alcoholic liver condition, nonalcoholic steatohepatitis (NASH), and scleroderma.

Moreover, in November, 2022, Intercept Pharmaceuticals, Inc. is an American biopharmaceutical corporation reported its strategies concentrated in designing its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH). Alcohol-related liver disease is presently the top indication for liver transplant listing in the U.S., with a significant growth in patients with sAH requiring liver transplantation. Presently, there are no drugs with an authorized indication for the treatment of sAH.  

COVID-19 Impact Analysis

Bunches of analysis have connected the pandemic to an upsurge in heavy drinking and a growth in alcohol-related liver disease (ARLD), with a disproportionate effect on females. Total casualties concerning alcohol grew 25% in 2020, with a 22% growth in alcohol-associated liver disorder casualties.

Moreover, according to the UK government rates of visits to hospitals for the alcoholic liver condition in the financial year ending 2021 stood at the highest at 45.5 per 100,000 population, a total of 24,544 admissions they have been since the financial year completing 2011, and are extremely more elevated compared to in the financial year ending 2020. In a recent analysis publicized in Liver International, investigators at Henry Ford Health System have uncovered that individuals hospitalized for alcoholic hepatitis rose a staggering 50% in the early months of the COVID-19 pandemic. Thus, the rise in the number of patients with alcohol-related liver diseases including hepatitis has led to an increase in the demand for the treatment positively impacting the global market.

Key Developments

  • In June 2023, DURECT Corporation, a biopharmaceutical corporation designing epigenetic treatments for the treatment of acute organ injuries and chronic liver conditions, finished enrollment in its Phase 2b AHFIRM clinical investigation (NCT04563026) examining larsucosterol for the treatment of individuals with extreme alcohol-associated hepatitis (AH), reaching its registration target of 300 patients.
  • In May 2023, Seal Rock Therapeutics, Inc., a clinical-stage corporation designing first-in-class and best-in-class kinase inhibitors, formed an out-licensing deal with GENFIT for the development of an injectable formulation of SRT-015 for an acute liver condition, including Acute-on-Chronic Liver Failure (ACLF).
  • In December 2022, Aldeyra Therapeutics, Inc. demonstrated target attention and advancement in the indications of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical investigation of ADX-629, a first-in-class orally administered investigational unique medicine nominee.

Market Companies

The major global players in the market include Sanofi, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, And Viatris Inc. among others.

Why Purchase the Report?

  • To visualize the global alcoholic hepatitis treatment market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of alcoholic hepatitis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global alcoholic hepatitis treatment market report would provide approximately 61 tables, 59 figures and 186 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
FAQ’s

  • The segments are By Drug Type, By Route of Administration, By Distribution Channel, and By Region.

  • Key players are Sanofi, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, And Viatris Inc. among others.

  • Asia Pacific is the fastest-growing region in the Alcoholic Hepatitis Treatment Market.

  • North America is the Largest Market Share in Alcoholic Hepatitis Treatment Market.
Related Reports
pharmaceuticals iconpharmaceuticals

Alcohol Dehydrogenase Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2023 May 29

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Non-alcoholic Steatohepatitis Supplement Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2023 November 01

Starting from

$3750

pharmaceuticals iconpharmaceuticals

Peptide Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 10

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Nanocapsules Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 03

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Ion Channel Modulators Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 May 07

Starting from

$4350

pharmaceuticals iconpharmaceuticals

DNA Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 May 20

Starting from

$4350

WhatsApp